secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVITA Medical, Inc. (RCEL)
CIK:        0001762303
Form:       8-K
Filed at:   2026-08-06T20:10:59+00:00
Accession:  0001193125-26-338011
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AVITA Medical Q2 revenue $21.7M (+18% YoY), raises FY2026 guidance to $86-89M, expects Q4 cash flow breakeven
--------------------------------------------------------------------------------

- Q2 net revenue $21.7M (record), up 18% YoY and 13% sequentially; gross margin 81.9% (+70 bps YoY).
- Net loss improved to $7.7M ($0.25 loss per share) from $9.9M ($0.38) in prior year; operating expenses down 6% YoY.
- Raised FY2026 revenue guidance to $86-89M (from $80-85M), representing 20-24% YoY growth; expects Q4 2026 cash flow breakeven.
- Cash, equivalents, and marketable securities $11.1M; net cash use improved to $3.2M from $9.9M in Q1.
- CMS proposed 2027 Medicare payment updates for RECELL, including national physician payment and increased facility rates.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1762303/000119312526338011/0001193125-26-338011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1762303/000119312526338011/rcel-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-338011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer